サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1287381

多形性膠芽腫治療薬市場：世界の産業動向、シェア、規模、成長機会、2023-2028年予測

Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 106 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
多形性膠芽腫治療薬市場：世界の産業動向、シェア、規模、成長機会、2023-2028年予測
出版日: 2023年03月18日
発行: IMARC
ページ情報: 英文 106 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場概要2023-2028年：

世界の多形性膠芽腫治療薬市場規模は、2022年に20億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に7.6%の成長率（CAGR）を示し、2028年までに31億米ドルに達すると予測しています。

多形膠芽腫は、グレードIVの星細胞腫としても知られ、脳細胞内で急速に広がり、近くの細胞にも感染するグレードIVの悪性脳腫瘍です。細胞の変性が早いため、脳を強く圧迫し、激しい頭痛や発作を引き起こします。正確な原因は不明ですが、ターコット症候群などの希少な遺伝性疾患を含むいくつかの要因が原因と考えられています。脳腫瘍の中でも致死率が高く、治療抵抗性であるため、診断後の生存期間が極めて短いことが特徴です。現在の治療方法は、外科的切除、化学療法、放射線療法などです。

腫瘍性疾患の有病率の増加や、世界の老年人口の増加が、市場成長を促進する主な要因の一つとなっています。さらに、神経膠腫幹細胞の抵抗性に対抗する高度な治療法の開拓も、市場成長にプラスの影響を及ぼしています。さらに、がんや関連疾患に対する分子バイオテクノロジーや遺伝子治療の研究開発活動が活発化し、さまざまな生物学的薬剤の開発が促進されています。これらの薬剤は、既存の治療法の副作用を軽減し、患者さんに広く受け入れられるよう支援しています。さらに、ヘルスケアインフラを改善するために世界中のいくつかの政府によって行われたイニシアチブと、さまざまな治療法が利用可能であるという認識の高まりが、市場の見通しをさらに明るいものにすると期待されています。

本レポートで扱う主な質問

  • 世界の多形性膠芽腫治療薬市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界の多形性膠芽腫治療薬業界に与えた影響は何か？
  • 世界の多形性膠芽腫治療薬産業における主要な地域市場は何か？
  • 薬剤タイプに基づく市場の内訳は？
  • 投与経路に基づく市場内訳は？
  • 分子タイプに基づく市場内訳は？
  • 流通チャネルに基づく市場内訳は？
  • 世界の多形性膠芽腫治療薬産業のバリューチェーンにおける様々なステージは何か？
  • 世界の多形性膠芽腫治療薬産業の主要な促進要因と課題は何か？
  • 世界の多形性膠芽腫治療薬産業の構造と主要プレイヤーは誰か？
  • 世界の多形性膠芽腫治療薬産業における競合の程度はどのようなものか？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者について
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要な業界動向

第5章 多形膠芽腫治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19のインパクト
  • 薬物タイプ別市場内訳
  • 投与経路別市場内訳
  • 分子タイプ別市場内訳
  • 流通チャネル別市場内訳
  • 地域別市場内訳
  • 市場予測

第6章 薬剤タイプ別市場内訳

  • テモゾロミド
    • 市場動向
    • 市場予測
  • ベバシズマブ
    • 市場動向
    • 市場予測
  • カルムスチン
    • 市場動向
    • 市場予測
  • 放射線増感剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 投与経路別市場内訳

  • 経口剤
    • 市場動向
    • 市場予測
  • 非経口剤
    • 市場動向
    • 市場予測

第8章 分子タイプ別市場内訳

  • 低分子化合物
    • 市場動向
    • 市場予測
  • バイオロジクス
    • 市場動向
    • 市場予測

第9章 流通チャネル別市場内訳

  • 病院
    • 市場動向
    • 市場予測
  • 薬局
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 地域別市場内訳

  • 北米
    • 市場動向
    • 市場予測
  • 欧州
    • 市場動向
    • 市場予測
  • アジア太平洋地域
    • 市場動向
    • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場予測
  • ラテンアメリカ
    • 市場動向
    • 市場予測

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Sun Pharmaceutical Industries
    • Celldex Therapeutics
    • Pfizer
    • F. Hoffmann La Roche
    • Bristol-Myers Squibb
    • Teva Pharmaceuticals
    • Exelixis
    • Angiochem
    • Arbor Pharmaceuticals
図表

List of Figures

  • Figure 1: Global: Glioblastoma Multiforme Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Glioblastoma Multiforme Treatment Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Glioblastoma Multiforme Treatment Market: Breakup by Drug Type (in %), 2022
  • Figure 4: Global: Glioblastoma Multiforme Treatment Market: Breakup by Route of Administration (in %), 2022
  • Figure 5: Global: Glioblastoma Multiforme Treatment Market: Breakup by Type of Molecule (in %), 2022
  • Figure 6: Global: Glioblastoma Multiforme Treatment Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Glioblastoma Multiforme Treatment Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 9: Global: Glioblastoma Multiforme Treatment Industry: SWOT Analysis
  • Figure 10: Global: Glioblastoma Multiforme Treatment Industry: Value Chain Analysis
  • Figure 11: Global: Glioblastoma Multiforme Treatment Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Glioblastoma Multiforme Treatment (Carmustine) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Glioblastoma Multiforme Treatment (Carmustine) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Glioblastoma Multiforme Treatment (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Glioblastoma Multiforme Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Glioblastoma Multiforme Treatment (Parenteral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Glioblastoma Multiforme Treatment (Parenteral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Glioblastoma Multiforme Treatment (Biologics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Glioblastoma Multiforme Treatment (Biologics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Glioblastoma Multiforme Treatment Market: Sales through Hospitals (in Million US$), 2017 & 2022
  • Figure 31: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Hospitals (in Million US$), 2023-2028
  • Figure 32: Global: Glioblastoma Multiforme Treatment Market: Sales through Pharmacies (in Million US$), 2017 & 2022
  • Figure 33: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Pharmacies (in Million US$), 2023-2028
  • Figure 34: Global: Glioblastoma Multiforme Treatment Market: Sales through Other Distribution Channels (in Million US$), 2017 & 2022
  • Figure 35: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Other Distribution Channels (in Million US$), 2023-2028
  • Figure 36: North America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: North America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Europe: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Europe: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Asia Pacific: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Asia Pacific: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Middle East and Africa: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Middle East and Africa: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Latin America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Latin America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2023-2028

List of Tables

  • Table 1: Global: Glioblastoma Multiforme Treatment Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 3: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 4: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Type of Molecule (in Million US$), 2023-2028
  • Table 5: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 6: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Glioblastoma Multiforme Treatment Market: Competitive Structure
  • Table 8: Global: Glioblastoma Multiforme Treatment Market: Key Players
目次
Product Code: SR1623A81_Report

Market Overview 2023-2028:

The global glioblastoma multiforme treatment market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.1 Billion by 2028, exhibiting a growth rate (CAGR) of 7.6% during 2023-2028.

Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.

Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global glioblastoma multiforme treatment market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on drug type, route of administration, type of molecule and distribution channel.

Breakup by Drug Type:

  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Radiosensitizers
  • Others

Breakup by Route of Administration:

  • Oral
  • Parenteral

Breakup by Type of Molecule:

  • Small Molecule
  • Biologics

Breakup by Distribution Channel:

  • Hospitals
  • Pharmacies
  • Others

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.

IMARC Group's latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.

Key Questions Answered in This Report:

  • How has the global glioblastoma multiforme treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global glioblastoma multiforme treatment industry?
  • What are the key regional markets in the global glioblastoma multiforme treatment industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the type of molecule?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global glioblastoma multiforme treatment industry?
  • What are the key driving factors and challenges in the global glioblastoma multiforme treatment industry?
  • What is the structure of the global glioblastoma multiforme treatment industry and who are the key players?
  • What is the degree of competition in the global glioblastoma multiforme treatment industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glioblastoma Multiforme Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Route of Administration
  • 5.6 Market Breakup by Type of Molecule
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Temozolomide
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bevacizumab
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Carmustine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Radiosensitizers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Type of Molecule

  • 8.1 Small Molecule
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Sun Pharmaceutical Industries
    • 15.3.2 Celldex Therapeutics
    • 15.3.3 Pfizer
    • 15.3.4 F. Hoffmann La Roche
    • 15.3.5 Bristol-Myers Squibb
    • 15.3.6 Teva Pharmaceuticals
    • 15.3.7 Exelixis
    • 15.3.8 Angiochem
    • 15.3.9 Arbor Pharmaceuticals